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Abstract
Despite recent advances in the treatment of malignant gliomas (World Health Organization grade 
III and grade IV tumors- Glioblastoma Multiforme, Anaplastic Astrocytoma and Anaplastic Oli-
godendroglioma), the overall prognosis remains poor. Tumor recurrence in malignant glioma is 
inevitable, and associated with reduced overall survival (OS). Bevacizumab is approved for use in 
progressive GBM as a second line treatment, and is associated with improvements in progression 
free survival (PFS). However, all GBM patients eventually recur on bevacizumab therapy, with a 
very short OS after bevacizumab failure.  No FDA-approved therapy is available for this clinical set-
ting. Etoposide crosses the blood-brain barrier and has activity in recurrent malignant gliomas. The 
use of bevacizumab with etoposide in recurrent malignant gliomas in the setting of bevacizumab 
resistance is evaluated in this review. Bevacizumab and etoposide combined therapy is associated 
with radiographic response and effectiveness in selected patients.
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Efficacy and safety of bevacizumab and etoposide combination
Background
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with 
an incidence rate of 3.17 per 100,000 person-years [1]. Despite multiple recent advances in the treat-
ment of malignant gliomas, the prognosis for recurrent malignant gliomas remains poor with 2-year 
overall survival of nearly 12% in population studies [1]. The use of surgical resection followed by ra-
diation and concomitant temozolomide chemotherapy has been well established as first-line therapy 
and is associated with a median survival of 14.6 months and 2-year overall survival of 27%[2,3]. Due 
to the limited ability of chemotherapies to cross the blood-brain barrier, multidrug resistance pro-
teins, and genetic and epigenetic heterogeneity, malignant gliomas are among the most challenging 
tumors to treat.
Vascular endothelial growth factor (VEGF) has been shown to be an important factor in tumor an-
giogenesis and is expressed in human gliomas [4-6]. Levels of VEGF correlate in increased microvas-
cular density and are seen more frequently in GBM than lower grade astrocytomas [5,7,8]. VEGF-A 
is mediated by VEGF-receptor-2 (VEGFR-2) and is the key mediator in malignant glioma angiogen-
esis. Inhibition of VEGF in GBM has been shown to improve survival [9]. Bevacizumab (Avastin®) 
is a humanized murine immunoglobulin (Ig) G1 monoclonal antibody that binds to and inhibits 
the activity of VEGF, preventing the interaction and activation of VEGF receptor tyrosine kinases 
VEGFR-1 and VEGFR-2 [10,11].
At time of tumor recurrence, the use of bevacizumab has been associated with improved clinical 
performance and a superior 6-month progression-free survival (PFS-6) of 42-50% [12,13]. The use of 
bevacizumab alone or in combination with CPT-11 (irinotecan, Camptosar®) yielded similar overall 
survival times of 9 months [13]. The significant objective response and favorable PFS seen in this 
phase II study resulted in U.S. Food and Drug Administration accelerated approval of bevacizumab 
for the treatment of recurrent GBM patients in 2009.
The optimal treatment of recurrent malignant gliomas that have failed bevacizumab therapy is not 
well established [14,15]. The prognosis in GBM after failure of bevacizumab is dismal with most 
patients developing progressive disease within 1 to 4 months and survival of 4 to 7 months after start 
of therapy in prospective studies [16-18]. Bevacizumab use in the recurrent setting of high-grade 
gliomas previously treated with anti-angiogenic agents was evaluated by Scott et al. [19]. The use 
of bevacizumab in 24 patients previously treated with various VEGF receptor tyrosine kinases pro-
duced radiographic response (PR) in 21% and stable disease in 58%. Bevacizumab salvage therapy 
resulted in a median time to progression (TTP) of 8 weeks, and median OS of 5.2 months after onset 
of therapy. As expected, the radiographic response and median TTP were less robust as compared to 
the initial anti-VEGF treatment.
In patients experiencing tumor progression while on bevacizumab therapy, surgery with further tu-
mor resection is complicated by wait times of up to four weeks to allow for clearance of drug, and 
minimize the risk of poor wound healing from impaired angiogenesis [20,21]. The importance of 
preventing wound breakdown is underscored by resultant CSF leaks and wound infections. In a 
study investigating the impact of bevacizumab on wound healing, significantly more patients who 
received preoperative bevacizumab developed healing complications than non-bevacizumab treated 
patients, 35% vs. 10%, respectively [20]. In the same retrospective study, risk of dehiscence increased 
from 12% in non-bevacizumab pre-operatively treated patients to 50% in those receiving bevaci-
zumab prior to craniotomy. The multiple surgical complications after bevacizumab use provide sup-
port for the need for further salvage treatment options in recurrent malignant gliomas. Decisions for 
surgical tumor debulking following bevacizumab use should be weighed against the risks of wound 
healing complications and infections.
25Reviews in Health Care 2014; 5(1)© SEEd All rights reserved
J. A. Carrillo, F. P. K. Hsu, J. Delashaw, D. A. BotaEfficacy and safety of bevacizumab and etoposide combination
Etoposide
Etoposide (VP-16, VePesid®) is a semi-synthetic derivative of podophyllotoxin, which acts as a cell 
cycle-specific agent blocking cells in the late S-G2 phase. Etoposide may be taken orally or intrave-
nously and readily crosses the blood-brain barrier where it causes tumor DNA damage via strand 
breakage involving inhibition of topoisomerase II [22]. Sensitivity to etoposide correlates to expression 
of the topoisomerase II (Topo II) enzyme in cell lines [23]. Acute toxicities associated with etoposide 
include nausea, vomiting and hypotension, while delayed toxicity includes alopecia, and bone marrow 
depression.
The activity of etoposide alone in recurrent supratentorial malignant glioma was described by Tirelli et 
al. and Fulton et al [24,25]. The Italian group described the use of etoposide given intravenously days 
1-5, dose escalated as tolerated, and repeated every 3 weeks in 22 patients. The Italian group observed 
clinical or radiologic response in 33% of patients.
In a different study, etoposide was given orally in a prolonged daily dosing as continuous therapy in 
order to achieve more uniform cell-cycle inhibition among those dividing cells [25]. Forty-six patients 
evaluated in this study of which 46% were GBM, and 20% were anaplastic oligodendrogliomas. Treat-
ment was well tolerated. Patient outcome analysis revealed a median time to progression (TTP) of 8.8 
weeks and median survival of 24.5 weeks. Radiologic objective response (CR+PR) was seen in 18% 
and total response (CR+PR+SD) was seen in 42%. Among those responding to treatment or stable, 
outcomes were improved with a median TTP was 16 weeks, and median survivals of 36-45 weeks.
Etoposide use in combined regimens
Temozolomide and etoposide
Data from a Phase I clinical trial by Korones et al. evaluated the use of temozolomide and escalating 
doses of oral etoposide in 29 recurrent malignant glioma patients [26]. In this study, glioblastoma and 
gliosarcomas (10%) comprised 76% of the patient population with the remaining 24% of patients hav-
ing either anaplastic astrocytoma or anaplastic oligoastrocytomas. In this Phase I trial, the informal 
outcomes to temozolomide and etoposide yielded a radiographic response rate of 7% and a total re-
sponse of 45%. The median duration of response was 4 months. Table I summarizes recurrent studies 
containing etoposide combination therapy.
Study Regimen n Tumor types
Response 
rate (%)
Total 
response 
rate (%)
Median 
PFS 
(weeks)
PFS-6 
(%)
Median 
OS 
(weeks)
Jeremic, 1992 [27] CBDCA + VP-16 38 GBM + AA 21 53 14 - 43.5
Watanabe, 2002 [28] CBDCA + VP-16 28 GBM + AA 14/36 57/79 - - 52/132
Franceschi, 2004 [29] CBDCA + VP-16 30 GBM + AA 24/30 64/70 16 33.3 36/40
Sanson, 1996 [30] Ifos + CBDCA + VP-16 36 GBM + AG 28 53 13 - 29
Aoki, 2010 [31] Ifos + CBDCA + VP-16 42 GBM 25 50 17 35 42.8
Schafer 2011 [32] Ifos + CBDCA + VP-16 13 GBM + AA 0  - 8 0 20
Table I. Recurrent studies containing etoposide combination therapy
CBDCA = carboplatin; Ifos=ifosfamide; VP-16 = etoposide
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Carboplatin and etoposide (CE regimen)
The combination of carboplatin and etoposide have been utilized by various investigators to capitalize 
on the synergistic activity of these compounds [27]. In this phase II study by Jeremic et al., 38 patients 
received carboplatin days 1-5, etoposide days 1-5 repeated every 4 weeks. Patients were 79% GBM and 
21% anaplastic astrocytoma, and tended to be heavily pretreated. The radiologic response rate was 21%, 
while total response rate was 53%. Median time to progression was 14 weeks and median survival time 
was 43.5 weeks.
The use of etoposide and carboplatin was evaluated by Watanabe et al. in a phase II study of 28 recur-
rent anaplastic astrocytoma and GBM patients [28]. The regimen consisted of intravenous carboplatin 
day 1, and etoposide days 1-5, and repeated every 6 weeks. Radiographic response was seen in 14% of 
GBM and 36% of AA patients, with total response seen in 57% of GBM and 79% of AA patients. The 
mean duration of the effect of treatment in those patients with total response was 9.3 months in AA 
and 4.1 months in GBM patients. The median survival time was 38.5 months and 13 months for AA 
and GBM, respectively.
The Italian group of Franceschi et al. investigated the use of etoposide and carboplatin in a phase II 
study of 30 recurrent GBM or AA [29]. Carboplatin was given intravenously days 1-3, and etoposide 
on days 1-3 every 4 weeks to a maximum of 12 cycles. Among the 25 GBM patients, the radiographic 
response rate was 24% and a total response rate of 64%. For GBM and AA patients, the overall radio-
graphic response rate was 30% and total response rate was 70%. The overall median time to progres-
sion was 4 months, with a PFS-6 of 33.3% and PFS-12 of 26.7%. The median time to progression was 3 
months in the GBM subgroup, with a PFS-6 of 20%. The overall median survival time was 10 months, 
with the GBM subgroup median survival time of 9 months. Response to treatment in this study may 
have been affected by the high performance status in this group of patients who were not heavily pre-
treated.
Ifosfamide, carboplatin and etoposide (ICE regimen)
In an early Phase II study by a French group, recurrent supratentorial malignant gliomas were treated 
with ifosfamide, carboplatin and etoposide (ICE) in 36 patients [30]. Investigators hoped to exploit the 
synergistic effects of etoposide, cisplatin and the alkylating agent ifosfamide, a combination regimen 
which has demonstrated a high therapeutic index in a variety of malignancies. Doses were increased 
according to hematological tolerance from ifosfamide days 1-3, carboplatin days 1-3, etoposide days 
1-3, and repeated every 4 weeks. This study resulted in a favorable objective radiologic response of 28% 
and a total response of 53%. The regimen demonstrated a median time to tumor progression of 13 
weeks, and a median survival of 29 weeks. Grade III and IV hematologic toxicities were seen in 42% of 
patients and resulted in one death from neutropenic sepsis.
A Phase II study of the ICE regimen was performed by the Japanese group in forty-two GBM patients 
at time of first recurrence [31]. Dosing for this study was more conservative than the Sanson study, 
consisting of ifosfamide days 1-3, carboplatin day 1, etoposide days 1-3, every 6 weeks. The study re-
vealed an objective response of 25% and a total response of 50%. The ICE regimen yielded a median 
6-month progression-free survival of 35%, a median PFS of 17 weeks, and a median survival time of 
10.7 months. Toxicities consisted mainly of alopecia, and Grade III and IV hematologic toxicities in 
17% of patients.
The use of etoposide as part of the ICE regimen in recurrent malignant gliomas was evaluated by the 
German group in 13 patients [32]. Patients received ifosfamide day 1-3, carboplatin day 1, and etoposide 
day 1-3, in a 6-week cycle. Three patients had been pretreated with bevacizumab, and another 3 patients 
went on to receive bevacizumab as part of further treatments. The ICE regimen resulted in a median PFS 
of 2 months, and median OS of 5 months. Unfortunately, this regimen yielded no survivors at 6-months, 
however, the population was quite heterogeneous and included 2 patients with KPS of <50.
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Etoposide plus anti-angiogenic agents in recurrent setting
The phase II study by Kesari et al. investigated the use of metronomic chemotherapy in recurrent ma-
lignant gliomas to assess whether continuous dosing would enhance disruption of the rapidly prolif-
erating endothelial cells seen in angiogenesis [33]. This study utilized a combination of etoposide and 
cyclophosphamide as cytotoxic agents, and thalidomide and celecoxib as the anti-angiogenic agents in 
48 patients. The patient population was heavily pretreated with a median of two prior recurrences. The 
radiologic objective response rate was 9% and the total response rate was 62.5%. The GBM patients 
in this series had a median PFS of 11 weeks, PFS-6 of 9%, and median OS of 21 weeks. The anaplastic 
glioma patients in this series performed better, as expected, with a median PFS of 14 weeks, PFS-6 of 
26%, and median OS of 42 weeks. The nominal antitumor activity that was seen with this metronomic 
regimen was thought to be possibly limited by the choice of anti-angiogenic agents used. Table II sum-
marizes the recurrent studies containing etoposide + anti-angiogenic agents.
Bevacizumab and etoposide
The effectiveness and safety of bevacizumab with concurrent etoposide chemotherapy are the focus of 
this article. A review of the literature yields scarce data on the use of bevacizumab with etoposide alone 
or in combination with other agents and is summarized below.
In a phase II two-arm trial, Reardon et al. evaluated metronomic etoposide or metronomic temodar 
with bevacizumab to treat twenty-three GBM patients that recurred on bevacizumab therapy [17]. 
Although the 52% achieved stable disease radiographically, there were no objective responses. In this 
heavily pre-treated group, the PFS-6 was 4.4% and subsequently at interim analysis both the etopo-
side and temozolomide arms were closed due to failure to meet predetermined efficacy outcomes. 
The patients in this study represent a heavily pre-treated group, most with > 2 previous instances of 
progressive disease prior to enrollment, and all patients had previously been treated with bevacizumab. 
Although both treatment arms were closed, the median PFS and median OS favored the etoposide 
group over the temozolomide group, 8.1 vs. 4.1 weeks, and 19 vs. 12.6 weeks, respectively. This phase 
II study provides evidence of efficacy in recurrent malignant gliomas treated with etoposide who have 
failed bevacizumab therapy.
In a larger phase II open-label trial, Reardon et al. evaluated metronomic etoposide plus bevacizumab 
for recurrent malignant glioma in 59 patients [34]. Oral etoposide was given for 21 days every 28 days 
and bevacizumab was administered every 14 days. Patients were a heavily pretreated group with 26% of 
GBM patients having received > 4 previous chemotherapeutic agents. The radiologic response rate was 
Study Regimen n
Tumor 
types
Response 
rate (%) 
GBM/AG
Total 
response 
rate (%)
Median PFS 
(weeks) 
GBM/AG
PFS-6 (%) 
GBM/AG
Median OS 
(weeks) 
GBM/AG
Kesari, 
2007 [33]
VP-16 + Cyclo + 
Thal + celecoxib
48 GBM + AG 9 62.5 11 9 42
Reardon 
2009 [34]
Bev + VP-16 59 GBM + AG 23/24 - 18/24 44.4/41 46.4/63.1
Francesconi 
2010 [36]
Bev + CBDCA + 
VP-16
6 GBM 83 - 19 22 29.9
Reardon 
2011 [17]
Bev + VP-16 vs. 
Bev + TMZ
23 GBM 0 52 8.1 - 19
Table II. Recurrent studies containing etoposide + anti-angiogenic agents
AG = AO, AMG, AA; Bev = bevacizumab; CBDCA = carboplatin; Cyclo = cyclophosphamide; 
Thal = thalidomide; TMZ = temozolomide; VP-16 = etoposide
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23% and 24% among those patients with GBM, and anaplastic gliomas, respectively. The median PFS 
was 18 weeks for GBM and 24 weeks for anaplastic gliomas. The PFS-6 was 44.4% and 41% amongst 
GBM and anaplastic gliomas, respectively. The median OS was 46.4 weeks for GBM and 63.1 weeks for 
anaplastic gliomas in this study. Toxicities were common in this study; grade 4 toxicities consisted of 
neutropenia (8%), thrombosis (3%), hypertension (2%), and infection (2%).
Retrospectively, the use of bevacizumab and etoposide in study of malignant gliomas comprised mostly 
of anaplastic astrocytomas who had failed bevacizumab after initial therapy with radiation and temo-
zolomide [35]. Among anaplastic astrocytomas the median PFS was 8 months and the median OS was 
28 months. In this small study, the GBM patients fared worse with a median PFS of 1.5 months and 
median OS of 3.5 months. This regimen can be a useful treatment for recurrent GBM in patients with 
bevacizumab failure.
Bevacizumab, carboplatin and etoposide (ACE regimen)
The Australian group described bevacizumab use combined with etoposide and carboplatin (ACE) 
in six recurrent GBM patients [36]. In this single institution retrospective analysis, the ACE regimen 
consisted of day 1, carboplatin area under the curve (AUC) 5 intravenously; days 1-3, etoposide intra-
venously; day 2, bevacizumab 10 mg/kg intravenously and this regimen was repeated every 3 weeks to 
a goal of 6 cycles. This regimen yielded a remarkable objective response rate (ORR) of 83%, although 
none of the patients had previously been treated with bevacizumab. The ACE treatment regimen yield-
ed progression-free survival at 6 months (PFS-6) of 22%, median progression-free survival of 19 weeks, 
and a median overall survival (OS) of 29.9 weeks. Toxicities were mild in general with significant tox-
icities largely due to myelosuppression with this regimen. Thrombocytopenia was mild with no grade 
three or four toxicities. While no neutropenic fever was observed, grade 3 neutropenia was observed 
in two patients.
Discussion
We evaluate in this review of the literature the efficacy and safety of bevacizumab and etoposide in 
recurrent malignant gliomas who have failed previous bevacizumab therapy. In recurrent malignant 
previously treated with anti-angiogenic agents, the use of etoposide and bevacizumab is associated with 
total response rates of 52-62.5%, PFS-6 of 9%-44.4%, and median PFS of 8.1-24 weeks [33,34,36,37]. 
Comparisons between these phase II studies is limited by the inherent differences in the patient popu-
lations among recurrent patients with respect to previous treatment regimens and number of recur-
rences.
In our experience at University of California Irvine, the combination of bevacizumab and etoposide 
has been well tolerated by patients with recurrent glioblastoma, with some neutropenia in this heavily 
pretreated group. The safety profile of the bevacizumab and etoposide combination is typically well 
tolerated. When bevacizumab and etoposide are given in combination after bevacizumab failure the 
toxicities have included grade three thrombocytopenia and neutropenia [35]. Myelosuppression re-
quiring dose modification of chemotherapy was not commonly seen with bevacizumab and etoposide 
combination treatment occurring in 28% of patients [17]. Toxicities increase when additional chemo-
therapies are added to bevacizumab and etoposide with dose reductions of cytotoxic chemotherapy 
needed in 36-83% of patients due to myelotoxicity [16,36] .
The performance of etoposide regimens without anti-angiogenic agents can be weighed against those 
that contain bevacizumab. The range of radiographic response rates appear to be lessened, which is 
somewhat expected from the larger number of patients in this group treated with prior anti-angiogenic 
therapy. In these patients the reduced enhancement resultant from vascular “normalization” results in 
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a dampening of the perceived radiographic response. The median PFS and PFS-6 data compare well 
with those from patients not previously treated with anti-angiogenic agents.
In this review of the use of etoposide in recurrent malignant gliomas, the activity of this chemo-
therapeutic agent is demonstrated alone and in a variety of regimens. Etoposide can be given with 
temozolomide where it yielded four month duration of response [26]. When combined with carbo-
platin, etoposide provides a median time to progression of 12-16 weeks [27-29]. The ICE regimen 
demonstrated a median PFS of 13-17 weeks in two studies, while a third heterogeneous group with 
poor performance status and some who previously failed bevacizumab showed modest median PFS 
of 8 weeks.
The literature reveals that etoposide regimens have activity in recurrent malignant gliomas. The utili-
zation of etoposide chemotherapy regimens in recurrent malignant gliomas is associated with radio-
graphic total response rates (PR+SD) of 50-79%, PFS-6 of 33.3-35%, and median PFS of 13-17 weeks. 
The radiographic and survival outcomes from etoposide combined chemotherapy regimens would ap-
pear to be superior to monotherapy treatment in the recurrent setting [33,34,36,37].
A notable limitation is that many of the trials cited in this review do not give reference to the DNA 
repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status of the pa-
tients enrolled, which limits inter-trial comparisons. MGMT is known to be a positive prognostic 
factor with increased survival compared to those with unmethylated MGMT promoter [38]. The 
treatment effects of MGMT methylation as they pertain to the use of topoisomerase II inhibitors and 
anti-VEGF therapy are likely minimal as etoposide treated tumors are not affected by MGMT-me-
diated resistance mechanisms [39]. In addition, the phenomenon of “pseudoresponse” also obscures 
the evaluation of those patients with favorable radiographic response to treatment [40,41]. Pseudo-
response is thought to occur due to normalization of cerebral vasculature with subsequent decreased 
contrast enhancement thus appearing improved despite unchanged nonenhancing tumor seen on 
MRI T2/FLAIR sequences [41,42]. The Radiologic Assessment in Neuro-Oncology (RANO) criteria 
was developed to improve and standardize the evaluation of tumors treated with anti-angiogenic 
agents thus leading more accurate determinations of true tumor progression than Macdonald crite-
ria assessments [43,44]. In some of the studies evaluating bevacizumab with etoposide the response 
is limited by analyses that failed to account for non-enhancing tumor seen on T2-weighted images/
FLAIR.
Conclusion
The optimal treatment of malignant gliomas that have failed previous bevacizumab therapy remains 
controversial. In recurrent malignant gliomas previously treated with anti-angiogenic agents, the use of 
etoposide with bevacizumab is safe and clinically active in a selected group of patients. New methods 
to be able to predict which patients will show benefit from this combination treatment are yet to be 
developed.
Questions for further research
In the recurrent setting, the optimal combination of chemotherapy regimen is not yet established 
and new treatments are needed.
The use of older conventional chemotherapy use in combination with newer anti-angiogenic tre-
atments should be further explored.
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